Kaiyin Fei

640 total citations
16 papers, 468 citations indexed

About

Kaiyin Fei is a scholar working on Rheumatology, Genetics and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Kaiyin Fei has authored 16 papers receiving a total of 468 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Rheumatology, 5 papers in Genetics and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Kaiyin Fei's work include Systemic Lupus Erythematosus Research (7 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Kaiyin Fei is often cited by papers focused on Systemic Lupus Erythematosus Research (7 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Kaiyin Fei collaborates with scholars based in United States, Japan and Germany. Kaiyin Fei's co-authors include Michael P. Sarras, Yan Li, Alexey A. Leontovich, Jinsong Zhang, Jinsong Zhang, Xiaoming Zhang, Kim Hung Lo, Robert Gordon, Ronald van Vollenhoven and Bevra H. Hahn and has published in prestigious journals such as Development, Developmental Biology and Annals of the Rheumatic Diseases.

In The Last Decade

Kaiyin Fei

16 papers receiving 462 citations

Peers

Kaiyin Fei

RHEUM

PALEO

IMMUN

Zixiao Yang China

Daisuke Sakurai Japan

Steven Hann United States

Érika Kague United Kingdom

Nathan Nelson-Maney United States

Cosimo Martinelli France

Lynn Graf United States

Taylor L. Reynolds United States

Hans Ulrik Møller Denmark

Grace A. Loredo United States

Zixiao Yang China

Kaiyin Fei

51 ×0.4

RHEUM

74 ×0.6

PALEO

57 ×0.5

IMMUN

279 ×2.6

27 ×0.4

Citations per year, relative to Kaiyin Fei Kaiyin Fei (= 1×) peers Zixiao Yang

Countries citing papers authored by Kaiyin Fei

Since Specialization

Citations

This map shows the geographic impact of Kaiyin Fei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaiyin Fei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaiyin Fei more than expected).

Fields of papers citing papers by Kaiyin Fei

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kaiyin Fei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaiyin Fei. The network helps show where Kaiyin Fei may publish in the future.

Co-authorship network of co-authors of Kaiyin Fei

This figure shows the co-authorship network connecting the top 25 collaborators of Kaiyin Fei. A scholar is included among the top collaborators of Kaiyin Fei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kaiyin Fei. Kaiyin Fei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Taylor, Peter C., Georg Schett, T. Huizinga, et al.. (2024). Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study. RMD Open. 10(2). e004278–e004278. 10 indexed citations

Taylor, Peter C., Fowzia Ibrahim, Bei Zhou, et al.. (2024). OA04 Efficacy and safety of nipocalimab in patients with moderate to severe active rheumatoid arthritis: the multicenter, randomised, double-blinded, placebo-controlled phase 2a IRIS-RA study. Lara D. Veeken. 63(Supplement_1). 2 indexed citations

Vollenhoven, Ronald van, Kenneth Kalunian, Thomas Dörner, et al.. (2022). Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases. 81(11). 1556–1563. 46 indexed citations

Vollenhoven, Ronald van, Bevra H. Hahn, George C. Tsokos, et al.. (2021). Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study. The Journal of Rheumatology. 49(4). 380–387. 22 indexed citations

Vollenhoven, Ronald van, George C. Tsokos, Robert Gordon, et al.. (2019). OP0041 MAINTENANCE OF EFFICACY AND SAFETY AND REDUCTION OF BILAG FLARES WITH USTEKINUMAB, AN INTERLEUKIN-12/23 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): 1-YEAR RESULTS OF A PHASE 2, RANDOMIZED PLACEBO-CONTROLLED, CROSSOVER STUDY. Annals of the Rheumatic Diseases. 78. 91–91. 3 indexed citations

Touma, Zahi, Dafna D. Gladman, Shawn Rose, et al.. (2019). THU0250 EARLY IMPROVEMENT IN SLEDAI-2K RESPONDER INDEX-50 PREDICTS SRI-4 RESPONSE IN A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF USTEKINUMAB (UST) IN SYSTEMIC LUPUS ERYTHEMATOSUS. Annals of the Rheumatic Diseases. 78. 402–403. 1 indexed citations

Vollenhoven, Ronald van, Bevra H. Hahn, George C. Tsokos, et al.. (2019). Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double‐Blind, Placebo‐Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus. Arthritis & Rheumatology. 72(5). 761–768. 41 indexed citations

Thorne, Carter, Tsutomu Takeuchi, George Karpouzas, et al.. (2018). Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D study. RMD Open. 4(2). e000731–e000731. 9 indexed citations

Takeuchi, Tsutomu, Carter Thorne, George Karpouzas, et al.. (2017). Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. Annals of the Rheumatic Diseases. 76(12). 2001–2008. 55 indexed citations

10.

Das, Siddharth Kumar, Vineeta Shobha, Milind Nadkar, et al.. (2016). Efficacy and safety of golimumab in Indian patients with rheumatoid arthritis: Subgroup data from GO‐MORE study. International Journal of Rheumatic Diseases. 19(11). 1083–1092. 6 indexed citations

11.

Ho, Tony W., Andrew P. Ho, Bernard Chaitman, et al.. (2012). Randomized, Controlled Study of Telcagepant in Patients With Migraine and Coronary Artery Disease. Headache The Journal of Head and Face Pain. 52(2). 224–235. 52 indexed citations

12.

Zhang, Xiaoming, Kaiyin Fei, Abdulbaki Aǵbaş, et al.. (2002). Structure and function of an early divergent form of laminin in hydra: a structurally conserved ECM component that is essential for epithelial morphogenesis. Development Genes and Evolution. 212(4). 159–172. 28 indexed citations

13.

Shimizu, Hiroshi, Xiaoming Zhang, Jinsong Zhang, et al.. (2002). Epithelial morphogenesis in hydra requires de novo expression of extracellular matrix components and matrix metalloproteinases. Development. 129(6). 1521–1532. 62 indexed citations

14.

Fei, Kaiyin, et al.. (2000). Molecular and biological characterization of a zonula occludens-1 homologue in Hydra vulgaris, named HZO-1. Development Genes and Evolution. 210(12). 611–616. 13 indexed citations

15.

Li, Yan, Alexey A. Leontovich, Kaiyin Fei, & Michael P. Sarras. (2000). Hydra Metalloproteinase 1: A Secreted Astacin Metalloproteinase Whose Apical Axis Expression Is Differentially Regulated during Head Regeneration. Developmental Biology. 219(1). 115–128. 54 indexed citations

16.

Fei, Kaiyin, et al.. (2000). Identification and characterization of hydra metalloproteinase 2 (HMP2): a meprin-like astacin metalloproteinase that functions in foot morphogenesis. Development. 127(1). 129–141. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact